Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05804526

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

An Open-label, Non-randomised, Multi-center Study to Evaluate the Safety， and Efficacy Off RC88 Combined With Sintilimab in AdvancedSolid Tumours

Status
Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
82 (estimated)
Sponsor
RemeGen Co., Ltd. · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate safety , clinical pharmacology and efficacy of intravenous RC88 combined with Sintilimab in advancedsolid tumours

Conditions

Interventions

TypeNameDescription
DRUGRC881.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
DRUGSintilimab InjectionSintilimab 200mg by intravenous (IV) infusion，every 3 weeks

Timeline

Start date
2023-07-19
Primary completion
2025-05-01
Completion
2025-12-01
First posted
2023-04-07
Last updated
2024-04-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05804526. Inclusion in this directory is not an endorsement.